Deals6 Feb 2025, 09:23 pm
Dr. Reddy's Laboratories Enters into Collaboration with Henlius for Commercialization of Daratumumab Biosimilar in US and Europe
AI Summary
Dr. Reddy's Laboratories SA, a wholly owned subsidiary of Dr. Reddy's Laboratories Ltd., has entered into a license agreement with Shanghai Henlius Biotech, Inc. for the development and commercialization of Henlius’s investigational daratumumab biosimilar candidate, HLX15, in the US and Europe. The agreement includes an upfront payment of $33 million and milestone payments up to a total of $131.6 million. Dr. Reddy’s gets exclusive rights to commercialize the subcutaneous as well as intravenous formulations of HLX15 in the US and Europe. This collaboration strengthens Dr. Reddy's biosimilars portfolio in the oncology area and leverages its commercial infrastructure for biosimilars in the US and Europe.
Key Highlights
- Dr. Reddy's Laboratories SA has entered into a license agreement with Shanghai Henlius Biotech, Inc. for the development and commercialization of Henlius’s investigational daratumumab biosimilar candidate, HLX15, in the US and Europe.
- The agreement includes an upfront payment of $33 million and milestone payments up to a total of $131.6 million.
- Dr. Reddy’s gets exclusive rights to commercialize the subcutaneous as well as intravenous formulations of HLX15 in the US and Europe.
- This collaboration strengthens Dr. Reddy's biosimilars portfolio in the oncology area.
- Dr. Reddy's commercial infrastructure for biosimilars in the US and Europe would be leveraged for commercialization of ‘Daratumumab’.